We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan)
The first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
Latest investor webcasts
Hear about our business updates and pipeline progress from the management team.
Annual General Meeting
Get information on our Annual General Meeting of Shareholders.
Latest documentation
Shareprice
Contact
Senior Vice President, Head of Investor Relations and Corporate Communications
Latest News
| 17 Apr 2024 | |
| 11 Apr 2024 | |
| 22 Mar 2024 | |
| 20 Mar 2024 |
Events
| Event | When |
|
Full Year 2023 and First Quarter 2024 Financial Reporting* |
May 21, 2024 |
|
Annual General Meeting of Shareholders |
June 13, 2024 |
|
Half Year 2024 Financial Reporting* |
July 25, 2024 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Equity story
Get an introduction to how we intend to translates the company strengths into sustainable value creation.
Financial overview
The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Get the latest highlights, financial results, company funding status, as well as a 5-year archive of our financial reporting.
Stock overview
The registered shares of Idorsia Ltd are listed on the SIX Swiss Exchange (symbol: IDIA). Get all the latest information about our stock and see what the covering analysts think about the company's future performance.
